Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
217 hedge funds and large institutions have $2.81B invested in Amicus Therapeutics in 2022 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 64 increasing their positions, 87 reducing their positions, and 30 closing their positions.
39% more call options, than puts
Call options by funds: $3.56M | Put options by funds: $2.56M
0.18% more ownership
Funds ownership: 108.19% → 108.36% (+0.18%)
3% less funds holding
Funds holding: 224 → 217 (-7)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
17% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 30
19% less capital invested
Capital invested by funds: $3.48B → $2.81B (-$666M)
26% less repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 87
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$54.1M |
| 2 |
Morgan Stanley
New York
|
+$33.6M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$18.8M |
| 4 |
State Street
Boston,
Massachusetts
|
+$13.4M |
| 5 |
PA
Perceptive Advisors
New York
|
+$9.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$19.4M |
| 2 |
AG
Artal Group
Luxembourg
|
-$18.8M |
| 3 |
Jennison Associates
New York
|
-$17M |
| 4 |
GH
Grosvenor Holdings
Chicago,
Illinois
|
-$11.1M |
| 5 |
Two Sigma Investments
New York
|
-$11.1M |
FOLD Hedge Fund Activity: Q1 2022 in Review
217 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q1 2022, worth a combined $2.81B — down 19% from $3.48B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of FOLD and 25 opened new positions — a net loss of 5 holders — while 87 trimmed existing stakes and 64 added.
The largest buyer was Janus Henderson Group, adding an estimated $54.1M. The largest seller was Jacobs Levy Equity Management, exiting entirely with an estimated $19.4M sold.
- 217 institutional investors held Amicus Therapeutics (FOLD) as of Q1 2022, down from 224 in Q4 2021.
- Funds reported $2.81B of Amicus Therapeutics stock for Q1 2022, down 19% quarter-over-quarter.
- 25 funds opened new Amicus Therapeutics positions in Q1 2022 and 30 closed out, a net change of -5 holders.
- The largest Amicus Therapeutics buyer in Q1 2022 was Janus Henderson Group, an estimated $54.1M added.
- The largest Amicus Therapeutics seller in Q1 2022 was Jacobs Levy Equity Management, an estimated $19.4M sold.
Based on aggregated 13F filings for Q1 2022.